

I hereby certify that this correspondence is being sent by facsimile transmission to:

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE -  
EXAMINING GROUP 1600**

Examiner G. Bwoldt at Fax No.: 1-703-305-3014

On October 9, 2001

**PATENT**  
2307AA-031220US  
90-160-5

TOWNSEND and TOWNSEND and CREW LLP

By: Paula A. Bwoldt

#29/9  
GND  
8/23/02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Steinunn Backkeskov et al.

Application No.: 08/838,486

Filed: April 7, 1997

For: IMPROVED METHODS FOR THE  
DIAGNOSIS AND TREATMENT OF  
DIABETES

Examiner: M. Tung

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1600**

**Box AF**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Final Office Action mailed April 24, 2001, please amend this application as follows:

**IN THE CLAIMS:**

Please cancel claims 60 and 61.

**REMARKS**

11. The office action indicates that all of the present claims are different in scope than those in the Florida patents. However, the office action has not stated what the differences in scope are, or addressed whether any differences are sufficient to confer patentable distinction. In addition, the office action has not stated whether the Florida patents can be overcome by declaration pursuant to 37 CFR 1.131 or MPEP 715.07(c) (attribution) or only by interference. Although applicants